Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.60 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 9/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 6/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.47 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.47 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.47 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.47 |
| ▸ | PRKACA | P17612 | 2/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27545277 | 0.86 | MAPK14 (0.80) | MAPK14TGFBR1CSNK1DCSNK1EMAPK13 | |
| SCHEMBL4913562 | 0.84 | MAPK14 (0.65) | MAPK14TGFBR1CSNK1DCSNK1EMAPK13 | |
| SCHEMBL7884407 | 0.83 | MAPK14 (0.68) | MAPK14TGFBR1CSNK1DCSNK1EMAPK13 | |
| SCHEMBL8860489 | 0.83 | MAPK14 (0.47) | MAPK14 | |
| SCHEMBL6876676 | 0.82 | MAPK14 (0.70) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL6880496 | 0.82 | MAPK14 (0.54) | MAPK14TGFBR1CSNK1DCSNK1EMAPK13 | |
| SCHEMBL1639781 | 0.81 | MAPK14 (0.72) | MAPK14TGFBR1CSNK1DCSNK1EMAPK13 | |
| SCHEMBL6881409 | 0.81 | MAPK14 (0.62) | MAPK14TGFBR1CSNK1DMAPK13MAPK12 | |
| SCHEMBL7890787 | 0.81 | MAPK14 (0.53) | MAPK14TGFBR1CSNK1DCSNK1EMAPK13 | |
| SCHEMBL1640964 | 0.81 | MAPK14 (0.59) | MAPK14TGFBR1CSNK1DCSNK1EMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1291346-B1 | Process for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORP (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-0708768-B1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-1291346-A1 | Process for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020188122-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2002-12-12 | — | — | US | disclosed |
| EP-1229035-A1 | Imine intermediates for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1227092-A2 | Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties | SmithKline Beecham Corporation (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-1227091-A2 | Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6222036-B1 | REACTING 2-THIO-4-DIMETHYOXYMETHYL-PYRIMIDINE WITH ACETIC ACID AND CATALYTIC AMOUNT OF CONCETRATED SULFURIC ACID TO PRODUCE 2-THIOPYRIMIDINE ALDEHYDE | SMITHKLINE BEECHAM CORPORATION | 2001-04-24 | — | — | US | disclosed |
| US-6150557-A | REACTING COMPOUND CONTAINING SECONDARY AMIDE GROUPS WITH BENZENESULFINIC ACID OR ITS DERIVATIVE IN PRESENCE OF ACID CATALYST | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-21 | — | — | US | disclosed |
| US-6103936-A | REACTING ALDEHYDE, SULFIDE, SULFONE, OR SULFOXIDE WITH FORMAMIDE IN PRESENCE OF ACID CATALYST, AND OPTIONALLY A DEHYDRATING AGENT | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
| CN-1050126-C | Tri-substituted imidazoles, their preparation and use and pharmaceutical compositions containing them | SMITHKLINE BEECHAM CORP (US) | 2000-03-08 | — | — | CN | disclosed |
| CN-1218801-A | Tri-substituted imidazoles, and process of their preparation and using the same and having their pharmic composition | SMITHKLINE BEECHAM CORP (US) | 1999-06-09 | — | — | CN | disclosed |
| US-5663334-A | CYTOKINE INHIBITORS FORMED BY REACTION OF IMINE WITH SULFUR SUBSTITUTED NITRILE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| US-5593991-A | ANTIINFLAMMATORY, CYTOKINE INHIBITOR, CYCLOOXYGENASE INHIBITOR | SMITHKLINE BEECHAM CORPORATION | 1997-01-14 | — | — | US | disclosed |
| US-5593992-A | CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| CN-1129447-A | Trisubstituted imidazoles having multiple therapeutic effects | SMITHKLINE BEECHAM CORP (US) | 1996-08-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188122-A1 | Novel compounds | IL2, IFNG, IL1RN | MAPK14 726/4885TGFBR1 512/4885CSNK1D 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.